Tag Archives: Aurolife Pharma

FDA) has issued Establishment Inspection Report (EIR) to subsidiary Aurolife Pharma’s plant in North

Aurobindo Pharma on Monday (August 17, 2026) said the U.S. Food and Drug Administration (U.S. [...]